Chronic Hepatitis B Market Size was approximately USD 1,500 Million in 2022, estimates DelveInsight

"The Chronic Hepatitis B market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2034). Furthermore, launching various multiple- Chronic Hepatitis B pipeline products will significantly revolutionize the Chronic Hepatitis B market dynamics"

The Chronic Hepatitis B market report provides current treatment practices, Chronic Hepatitis B emerging drugs, market share of individual therapies, and current and forecasted 7MM a Chronic Hepatitis B market size from 2020 to 2034. The report also covers current Chronic Hepatitis B treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Key Takeaways from the Chronic Hepatitis B Market Research Report
• According to DelveInsight estimates, there were around 3,04,900 and 53,800 cases of compensated and decompensated liver in Japan in 2022. These cases are projected to increase during the forecast period.
• In the United States, approximately 55% of the patient share is attributed to males, whereas around 40% of females suffer from Chronic Hepatitis B.
• The leading companies working in the Chronic Hepatitis B Market include Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Janssen Sciences Ireland, Assembly Biosciences, Janssen and Arrowhead Pharmaceuticals, Roche, Vir Biotechnology, Novartis, and others.
• Promising Chronic Hepatitis B Pipeline Therapies in the various stages of development include Tenofovir Alafenamidem, VIR-221, Selgantolimod, telbivudine, lamivudine, pegylated interferon-alfa 2a, and others.
May 2024:- Hoffmann-La Roche- A Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection. This is a first in human (FIH), multi-center, dose-finding, and dose-escalation Phase I clinical study of RO7565020 to investigate the safety and tolerability and to characterize the pharmacokinetics and pharmacodynamics following single and/or multiple doses of RO7565020 in healthy participants and/or virologically suppressed participants with chronic hepatitis B (CHB).
May 2024:- Gilead Sciences- A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects With Chronic Hepatitis B Virus Infection. The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
May 2024:- Arbutus Biopharma Corporation- A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects With Chronic HBV Infection. This is a phase 2a, open-label, multicenter study investigating the safety, tolerability, and antiviral activity of durvalumab administered at targeted times during a 48-week treatment period of imdusiran in virologically-suppressed CHB subjects.

Discover more about therapies set to grab major Chronic Hepatitis B Market Share @ Chronic Hepatitis B Market Size- https://www.delveinsight.com/report-store/chronic-hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Hepatitis B Overview
Chronic Hepatitis B (CHB) has been described as "a heterogeneous disease with markedly variable levels of viral replication and liver disease activity". It is characterized by liver injury mediated by a T-cell immune response targeting hepatocytes that express viral antigens.

Chronic Hepatitis B Epidemiology Segmentation in the 7MM
• Total Chronic Hepatitis B Prevalent Cases
• Total Chronic Hepatitis B Diagnosed Prevalent Cases
• Chronic Hepatitis B Gender-specific Diagnosed Prevalent Cases
• Chronic Hepatitis B Age-specific Diagnosed Prevalent Cases
• Chronic Hepatitis B Type-specific Diagnosed Prevalent Cases
• Total Chronic Hepatitis B Treated Cases

Download the report to understand which factors are driving Chronic Hepatitis B Epidemiology Trends @ Chronic Hepatitis B Epidemiological Insights- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Hepatitis B Marketed Drugs

• VEMLIDY (tenofovir alafenamide): Gilead Sciences
VEMLIDY is an HBV nucleoside analog reverse transcriptase inhibitor. It is approved for treating Chronic Hepatitis B infection in adults and pediatric patients 12 years and older with compensated liver disease. Recently, VEMLIDY received approval for pediatric patients 12 years and older with Chronic Hepatitis B infection with compensated liver disease in November 2022 in the United States. However, the drug was first approved in the United States and Japan, followed by approvals in the EU (2017) for adult patients with Chronic Hepatitis B.

Chronic Hepatitis B Emerging Drugs

• Bepirovirsen (GSK3228836): GlaxoSmithKline/Ionis Pharma
Bepirovirsen (GSK3228836) is an investigational antisense oligonucleotide (ASO) designed to specifically recognize the RNA that the hepatitis B virus uses to replicate itself in the infected liver cells (hepatocytes) and make the viral antigens (proteins) that facilitate chronicity of the disease by helping avoid clearance by the immune system. The assets were in-licensed by GSK from Ionis Pharmaceuticals in August 2019.

To know more about Chronic Hepatitis B Treatment options, visit @ Chronic Hepatitis B Drugs- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Hepatitis B Drugs Market
The existing Chronic Hepatitis B treatment is mainly dominated by antiviral drugs such as entecavir, VEMLIDY, VIREAD, telbivudine, adefovir dipivoxil, and lamivudine. Lamivudine was the first NA to be given the go-ahead by US FDA for treating Chronic hepatitis B. The drug was given adult approval in 1998, while pediatric approval for children aged 2-17 was given in 2001. But since 1995, this drug has been used and licensed for treating HIV infection. With few side effects, it can be used successfully in various patients. However, lamivudine therapy for a prolonged time is linked to significant rates of drug resistance, which cause virological relapse and biochemical flare. Lamivudine is suggested as a second-line therapy for managing Hepatitis B.

Chronic Hepatitis B Market Outlook
Chronic Hepatitis B treatment in the US is entering a new era with changing dynamics. To this date, several drugs have been approved by the US FDA to treat Chronic Hepatitis B: interferon-alpha and pegylated interferon-alpha, nucleoside analogs (NA), and nucleotide analog prodrugs. Oral antiviral medications include VIREAD (tenofovir disoproxil), VEMLIDY (tenofovir alafenamide), BARACLUDE (entecavir), TYZEKA or SEBIVO (telbivudine), HEPSERA (adefovir dipivoxil), and lamivudine (Epivir-HBV, Zeffix, or Heptodin). The aforementioned therapies help fight the virus and slow its ability to damage the liver.

Learn more about the Chronic Hepatitis B Pipeline Therapies in clinical trials @ Chronic Hepatitis B Market Landscape- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Hepatitis B Market Report
• Coverage-7MM
• Study Period- 2019-2032
• Chronic Hepatitis B Companies- Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Janssen Sciences Ireland, Assembly Biosciences, Janssen and Arrowhead Pharmaceuticals, Roche, Vir Biotechnology, Novartis, and others.
• Chronic Hepatitis B Pipeline Therapies- Tenofovir Alafenamidem, VIR-221, Selgantolimod, telbivudine, lamivudine, pegylated interferon-alfa 2a, and others.
• Chronic Hepatitis B Market Dynamics: Ataxia Telangiectasia Market Drivers and Barriers
• Chronic Hepatitis B Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Chronic Hepatitis B Drugs in development @ Chronic Hepatitis B Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Chronic Hepatitis B Market Overview at a Glance
4. Executive Summary of Chronic Hepatitis B
5. Epidemiology and Market Methodology
6. Disease Background and Overview
7. Diagnosis of Hepatitis B Infection
8. Current Treatment Practices
9. Epidemiology and Patient Population
10. Patient Journey
11. Key Endpoints in Chronic Hepatitis B Clinical Trials
12. Marketed Therapies
13. Emerging Therapies
14. Discontinued Drugs
15. Chronic Hepatitis B: The 7MM Analysis
16. Market Access and Reimbursement
17. KOL Views
18. SWOT Analysis
19. Unmet Needs
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Other Important Links-

Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Vulvar Cancer Market- https://www.delveinsight.com/report-store/vulvar-cancer-market
Vascular Grafts Market- https://www.delveinsight.com/report-store/vascular-grafts-market
Acne Vulgaris Market- https://www.delveinsight.com/report-store/acne-vulgaris-av-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Angiofibroma Market- https://www.delveinsight.com/report-store/angiofibroma-market
Atopic Dermatitis Market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Tendonitis Market- https://www.delveinsight.com/report-store/tendonitis-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Ascites Market- https://www.delveinsight.com/report-store/ascites-market
Systemic Lupus Erythematosus Market- https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market
Post Operative Pain Management Market- https://www.delveinsight.com/report-store/post-operative-pain-management-market
Cxcr Inhibitors Market- https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
Androgen Receptor Inhibitor Market- https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
STS Devices Market- https://www.delveinsight.com/report-store/sts-devices-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.